numares AG, a leader in NMR metabolomics-based diagnostics, has developed a novel multi-marker approach – GFRNMR – to determine kidney function using simple serum tests. The combination of multiple renal biomarkers can exceed the diagnostic limitations of the established method for estimating GFR (glomerular filtration rate). The assessment of kidney function is extremely important for […]

In the first part of the series ESG Investing (Environment, Social, Governance), Dr. André Zimmermann, Partner and Head of ESG at SHS, wrote about the basic principles of socially responsible investing. Today, we will take a closer look at how SHS implements ESG and SRI (Socially Responsible Investing) in concrete terms. Since its foundation almost […]

After leading the Balingen-based homecare specialist medigroba GmbH on an impressive growth course over the past five years, SHS is now selling the company to Löwenstein Group. The medigroba management is confident that it will be able to continue on its successful course within Löwenstein Group, because there are more and more people who are […]

Chronic back pain is one of the most common pains in industrial societies; and sometimes it is so unbearable that only surgery with a spinal implant can help. Blue Ocean Spine GmbH is developing new types of spinal implants that can be individually adapted in situ, some of which even manage without additional screw fixation. […]

In future, we will introduce the SHS senior advisors to you here. The experience of these experts plays an important role for us in the investment process and benefits not least our portfolio companies. After completing his engineering studies, Heinz Jacqui worked for many years in top management positions at globally successful medium-sized companies. Most […]

The German Pain Society estimates the number of chronic pain patients in Germany alone at around 23 million people. These include, for example, cancer patients who suffer from severe, chronic pain that can usually only be treated with opioid analgesics. For these patients, among others, the SHS portfolio company Develco Pharma develops and produces orally […]

Unquote reports on the sale of homecare specialist Medigroba to the Löwenstein Group. The deal is SHS’s second exit of 2021; the GP sold its stake in Crystal LaserSystems to Silver Investment Partners in March 2021. SHS expects to launch fundraising for its next fund later in 2021.

In the course of a successful succession arrangement, Tübingen-based SHS Gesellschaft für Beteiligungsmanagement mbH sells its shares in medigroba GmbH to Löwenstein Group With SHS as majority shareholder, medigroba has more than doubled revenue and tripled EBITDA in the last four and a half years Due to the continuing trend towards outpatient care, the medium-sized […]

ESG, SRI, impact investing: when did this start, and what is its importance in the healthcare sector?

AMW GmbH announced today that Dr. Konstantin Petropoulos has been appointed Chief Executive Officer (CEO) effective March 15, 2021 This expands Dr. Friedrich Tegel and Philipp Karbach to the existing management team.

The industry magazine “Plattform Life Sciences” asked investors and financing advisors about the mood after the Corona year 2020 and, among others, asked SHS partner Manfred Ulmer-Weber about current financing trends and how life science investors like SHS see the world “after” COVID-19.

In a Podcast Caroline Sai of EIT Health and our Partner Andre Zimmermann are discussing in which ways the new MDR is heavily affecting the whole European Medtech area – from start-ups to established medium-sized companies. In addition, SHS is out-lining in which way medium-sized companies and investors can team-up not only to overcome the economical challenges of the MDR for Medtechs but to prosper.